BioWorld. Link to homepage.

Clarivate
  • BioWorld
  • BioWorld Science
  • BioWorld Asia
  • Data Snapshots
    • Biopharma
    • Medical technology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • NME Digest
  • Special reports
    • Infographics: Dynamic digital data analysis
    • Trump administration impacts
    • Med-tech outlook 2026
    • Under threat: mRNA vaccine research
    • BioWorld at 35
    • Biopharma M&A scorecard
    • Bioworld 2025 review
    • BioWorld MedTech 2025 review
    • BioWorld Science 2025 review
    • Women's health
    • China's GLP-1 landscape
    • PFA re-energizes afib market
    • China CAR T
    • Alzheimer's disease
    • Coronavirus
    • More reports can be found here

BioWorld. Link to homepage.

  • Sign In
  • Sign Out
  • My Account
Subscribe
BioWorld - Friday, April 10, 2026
Home » Topics » Cardiovascular, Medical technology

Cardiovascular, Medical technology
Cardiovascular, Medical technology RSS Feed RSS

Happy Birthday Barbie!

March 9, 2012
By Amanda Pedersen
It’s hard to believe by looking at the 11.5” cultural icon, but Barbie is celebrating her 53rd birthday today. Perhaps her life in plastic is the reason she looks so great for her age but the Society for Vascular Surgery is putting a different spin on the doll’s birthday – noting that Barbie has always maintained an active lifestyle. The organization is using the milestone to highlight the importance of women’s vascular health issues. “Women in their 50s should remain active,” said Kellie Brown, MD, a member of the Society for Vascular Surgery. “Thirty minutes of exercise daily, eating healthy,...
Read More

TAVR: What it says about FDA and CMS

Feb. 29, 2012
By Mark McCarty
The story has been out for a while about transcatheter aortic valve replacement (TAVR), so maybe it's time to project into the future. Before we head there, however, we should revisit the past. The pivotal event in this story is the drug-eluting stent, a device that gave birth to what FDA's Bram Zuckerman, MD, described as the DES trauma. The DES story is twofold; rapid physician adoption and late-stent thrombosis (LST). FDA saw the rate of adoption as an unruly and harmful stampede because of LST, but...
Read More

Curious about your heart rate? There's an app for that

Dec. 22, 2011
By Amanda Pedersen
It’s that time of year again when millions of us in the U.S. make New Year’s resolutions to improve ourselves in some grand way – often by means of getting in shape and/or leading an overall healthier lifestyle. And this year we’re sticking to it – right? Well, at least until mid-February. Fortunately this year there are dozens of free mobile health apps that can help us with our resolutions - or at least make it more fun trying.  There’s literally an app for everything from helping you lose weight to tracking your menstrual cycle, monitoring your heart rate, and...
Read More

Changing nature of healthcare is reflected in new push for services to become a retail commodity

Dec. 7, 2011
By Jim Stommen
“Okay, hon. I’m headed over to MammothMart. Need to grab some beer and munchies for the Monday night game, a replacement shower head for the bathroom and maybe that new Michael Connelly book." “I might as well get the oil change and lube done on your SUV while I’m there. And while I’m there, I’ll get that loose pair of glasses tightened at the optical shop. Oh yeah, and I guess I’ll have them check out that stomach pain I’ve been having off and on.” If any of the above seems to border on crossing the line between imagination and...
Read More

The G18

Nov. 23, 2011
By Amanda Pedersen
So far I’ve chronicled my visit to Canada by focusing on what I’ve learned so far about the country’s focused efforts on growing its medical device industry – which is, of course, the primary purpose of the Advanced Medical Devices Media Tour, organized by the Ontario Ministry of Economic Development and Innovation (MEDI). But in addition...
Read More

Being there first: Personalized medicine and the investor

Nov. 10, 2011
By Mark McCarty
I don't directly invest in med-tech, but attending Transcatheter Cardiovascular Therapeutics for five years makes me wonder how an investor separates winners and losers. I know TCT 2011 has both, but which are which? Asking about the patient population is just the start of the investor conversation, but in an age in which indications for use are becoming increasingly narrow, it's probably the last question, too. After all, we have radio-frequency ablation devices approved for paroxysmal atrial fibrillation, but not for persistent or long-standing afib....
Read More

Medtronic plans to enter ED market

Nov. 4, 2011
By Omar Ford
Medtronic has the potential to be a trend setter with its attempt to have drug eluting stents (DES) treat erectile dysfunction (ED). The device maker recently moved one step closer in this effort as it reported that it had completed its ZEN (Zotarolimus-Eluting Peripheral Stent System for the Treatment of Erectile Dysfunction in Males with Sub-Optimal Response to PDE5 Inhibitors), feasibility study. The device, which hasn't been named yet, will be inserted into the pelvic area of the body. More specifically the stent is delivered using a catheter threaded up to the pelvis, where the pudendal artery is located. It...
Read More

A tinkerer at heart, Wilson Greatbatch epitomized what that means to medicine

Oct. 4, 2011
By Jim Stommen
A prolific inventor who died last week in upstate New York at the age of 92, Wilson Greatbatch is credited with more than 325 patents, including coming up with the first practical implantable pacemaker. Besides being memorialized for those breakthroughs, he truly should be viewed as an inveterate tinkerer who as much as any single individual represents the very best of what that term means to medical innovation. While the invention of the...
Read More

The Good, the Bad and the Ugly: Third-party coverage requests

Sep. 30, 2011
By Mark McCarty
As a member of the trade press, I get a kick out of how routinely some people in the mainstream media and the population at large routinely assume that device makers are driven by greed and that doctors are morally flawless creatures who spend all their spare time pondering the public weal and woe, continuously devising ways to ensure their passage through the Pearly Gates with constant acts of selflessness. And then I see the parties weighing in on the question of Medicare coverage for the Sapien aortic valve made by...
Read More

Could Medtronic eventually shed Infuse?

Sep. 26, 2011
By Omar Ford
After Johnson & Johnson (J&J, New Brunswick, New Jersey) said that it was going to discontinue its work in the drug eluting stent (DES) market, my eyes then began to focus on Medtronic (Minneapolis), which has recently taken a beating in the wallet and court of public opinion with its bone growth product, Infuse. I began asking myself how much longer before Medtronic finally abandons ship on this application. I mean if there ever was a shining example of a device that has caused problems for a company then Infuse is it. The med-tech juggernaut was dealt what one would...
Read More
Previous 1 2 … 98 99 100 101 102 103 104 105 106 Next

Popular Stories

  • Today's news in brief

    BioWorld
    BioWorld briefs for April 10, 2026.
  • Hengrui discovers new Nav1.8 blockers

    BioWorld Science
    Researchers from Jiangsu Hengrui Pharmaceuticals Co. Ltd. and Shanghai Hengrui Pharmaceutical Co. Ltd. have patented new sodium channel protein type 10 subunit α...
  • Cancer and blood cells

    Hematopoietic stem cell research points to leukemia’s early roots

    BioWorld Science
    Hematopoietic stem cell (HSC) research over the past century has shown that leukemia may be driven by an invisible hand of inflammation. The bone marrow and...
  • News in brief

    BioWorld Asia
    BioWorld Asia briefs for April 7, 2026
  • Connecting puzzle pieces

    Korsana boosts Alzheimer’s work with reverse merger, $380M financing

    BioWorld Science
    Just over a month after emerging from stealth and disclosing a $150 million series A, Korsana Biosciences Inc. is making the leap to the public market via a...
  • BioWorld
    • Today's news
    • Analysis and data insight
    • Clinical
    • Data Snapshots
    • Deals and M&A
    • Financings
    • Medical technology
    • Newco news
    • Opinion
    • Regulatory
  • BioWorld Science
    • Today's news
    • Biomarkers
    • Cancer
    • Conferences
    • Endocrine/metabolic
    • Immune
    • Infection
    • Neurology/psychiatric
    • NME Digest
    • Patents
  • BioWorld Asia
    • Today's news
    • Analysis and data insight
    • Australia
    • China
    • Clinical
    • Deals and M&A
    • Financings
    • Newco news
    • Regulatory
    • Science
  • More
    • About
    • Advertise with BioWorld
    • Archives
    • Article reprints and permissions
    • Contact us
    • Cookie policy
    • Copyright notice
    • Data methodology
    • Infographics: Dynamic digital data analysis
    • Index insights
    • Podcasts
    • Privacy policy
    • Share your news with BioWorld
    • Staff
    • Terms of use
    • Topic alerts
Follow Us

Copyright ©2026. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing